TScan Therapeutics, Inc.

US$0.19As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:TCRXHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (52.66%)
Div yield —
ROE (95.80%)
Biotechnology
Beta (5Y) 1.19
PE TTM —
TSR TTM (90.31%)
Mkt cap US$12.74M
ROIC (34.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.233
23.79%
(73.12%)
Hold 11|9|6|9|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
—
—
—
—
0.86%
(6.02%)
2.57%
(0.63%)
Revenue$M
1.071
1.133
1.126
1.127
4.67%
12.31%
7.84%
10.64%
Peers (US$12.74M)
Cap (US$)
PE
12.87M
—
12.79M
—
Capital
TTM
5Y
10Y
Leveragex
0.823
(0.433)
(0.495)
EBIT/Intx
0.131
0.431
0.412
Own earn%
(28.63)
(81.21)
(81.03)
Sh yield%
39.95
37.93
36.80
Owners
Insiders/Inst%
11.43
64.32
Short interest%
3.92
SBC / revenue%
4.28
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
20–24
$1 testx
0.0
Incr. ROIC%
0